Ackman’s Platform Specialty In $3.5B Deal With Arysta LifeScience – ValueWalk Premium
Bill Ackman

Ackman’s Platform Specialty In $3.5B Deal With Arysta LifeScience

Platform Specialty Products Corp (NYSE:PAH), a Miami-based chemical company, has agreed to acquire Arysta LifeScience, an Ireland-based agriculture chemical maker at $3.5 billion, including debt. Permira, Arysta’s private equity owner, earlier contemplated a U.S. IPO, although the firm progressed with the sale as Platform Specialty’s interest grew.
Ackman’s stake in Platform Specialty
Pershing Square Capital Management, the activist hedge fund headed by Bill Ackman, initiated . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

0